These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34554274)

  • 1. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
    Corrado E; Dattilo G; Coppola G; Morabito C; Bonni E; Zappia L; Novo G; de Gregorio C
    Eur J Clin Pharmacol; 2022 Jan; 78(1):19-25. PubMed ID: 34554274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    Hu J; Wu Y; Zhou X; Wang X; Jiang W; Huo J; Shan Q
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):445-451. PubMed ID: 33030857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.
    Yin H; Ma L; Zhou Y; Tang X; Li R; Zhou Y; Shi J; Zhang J
    Heart Vessels; 2024 Aug; 39(8):673-686. PubMed ID: 38635062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test.
    Malfatto G; Ravaro S; Caravita S; Baratto C; Sorropago A; Giglio A; Tomaselli M; Parati G; Villani A
    Acta Cardiol; 2020 Dec; 75(8):732-736. PubMed ID: 31577528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
    Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience.
    Dattilo G; Bitto R; Correale M; Morabito C; Vaccaro V; Laterra G; Casale M; Crea P; DI Bella G; Luzza F; Migliorato A; Katsiki N; DE Gregorio C
    Minerva Cardiol Angiol; 2022 Oct; 70(5):555-562. PubMed ID: 33823573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.
    Bhat TS; Hafeez I; Tak SF; Mattoo A; Patigaroo AR; Khan A; Lone AA; Beig JR
    Indian Heart J; 2022; 74(3):178-181. PubMed ID: 35483448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
    Dereli S; Kılınçel O; Çerik İB; Kaya A
    Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled study.
    Nesterov SV; Räty J; Nammas W; Maaniitty T; Galloo X; Stassen J; Laurila S; Vasankari T; Huusko J; Bax JJ; Saraste A; Knuuti J
    Eur J Heart Fail; 2024 Jan; 26(1):117-126. PubMed ID: 37905338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.